Ren YX, et al. - In this study performed on a cohort of 354 consecutive patients with newly diagnosed T1N0M0 triple-negative breast cancer (TNBC) between January 2008 and December 2015 from the Fudan University Shanghai Cancer Center, researchers assessed the influence of adjuvant chemotherapy and the benefit of taxanes by using univariate and multivariate survival analyses to compare patients treated with adjuvant chemotherapy with/without taxane addition. Participants were followed-up for a median of 45 months duration. They noted 92.4% of patients were treated with chemotherapy and 94.5% and 83.6% were the estimated 5-year recurrence-free survival (RFS) rates of patients with and without adjuvant chemotherapy, respectively. A significant benefit for RFS was reported in association with adjuvant chemotherapy and a lack of lymphovascular invasion in multivariate analysis. They found that recurrence-free survival in T1c TNBC patients but not in T1b was improved by adjuvant chemotherapy. In T1N0M0 TNBC patients, RFS benefits might be sufficiently offered by anthracycline-based taxane-free regimens.